Quark Pharmaceuticals, Inc.

Contact

About Quark Pharmaceuticals

Quark Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company for the discovery and development of novel RNAi-based therapeutics.

News about Quark Pharmaceuticals

23-Mar-2011 | research and development

In a Phase 2 Study Quark Pharmaceuticals' PF-04523655 Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months

Quark Pharmaceuticals, Inc. announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study. This study evaluated the ...

Read news

01-Aug-2008 | research and development

Silence Therapeutics to receive $1.9m Milestone Payment as Pfizer and Quark commence Phase II Trial

Silence Therapeutics plc announced that its partner, Quark Pharmaceuticals Inc together with Pfizer, has commenced a Phase II clinical trial with RTP-801i- ...

Read news

03-Aug-2007 | business & finance

Silence Therapeutics And Quark Pharmaceuticals Expand Strategic Licensing Agreement.

Silence Therapeutics plc and Quark Pharmaceuticals, Inc., announced an expansion of their current strategic technology licensing agreement. In April 2005 ...

Read news

Show more news about Quark Pharmaceuticals

Get the life science industry in your inbox

Quark Pharmaceuticals, Inc.

About Quark Pharmaceuticals

News about Quark Pharmaceuticals

In a Phase 2 Study Quark Pharmaceuticals' PF-04523655 Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months

Silence Therapeutics to receive $1.9m Milestone Payment as Pfizer and Quark commence Phase II Trial

Silence Therapeutics And Quark Pharmaceuticals Expand Strategic Licensing Agreement.

Here you will find Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc.